Peter Collum
Finanzdirektor/CFO bei REDX PHARMA PLC
Vermögen: 29 040 $ am 30.04.2024
Aktive Positionen von Peter Collum
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| REDX PHARMA PLC | Finanzdirektor/CFO | 05.05.2021 | - |
Karriereverlauf von Peter Collum
Ehemalige bekannte Positionen von Peter Collum
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| PHARNEXT SCA | Finanzdirektor/CFO | 26.06.2019 | 01.04.2021 |
MTS Health Partners LP
 MTS Health Partners LP Investment Banks/BrokersFinance MTS Health Partners LP provides strategic and financial advisory services to healthcare companies from global corporations to venture backed businesses. Its strategic advisory alternatives include mergers, acquisitions, company sales, divestitures, recapitalizations, restructurings, general strategic advisory, financing oversight and oversight opinions. The firms financing solutions include traditional private convertible preferred issuances, cross-over focused convertible transactions, common stock and structured/convertible PIPEs, registered direct and acquisition financings, secondary sales, special situations, structured debt financings and royalty monetization. The company was founded by Curtis Scott Lane in 2000 and is headquartered in New York, NY. | Corporate Officer/Principal | 01.06.2009 | 01.06.2019 |
| MERRILL LYNCH PREFERRED CAPITAL TRUST I | Corporate Officer/Principal | 01.01.2009 | 01.01.2009 |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Corporate Officer/Principal | 01.01.2000 | 01.01.2000 |
Ausbildung von Peter Collum
| Rutgers State University of New Jersey | Undergraduate Degree |
| The University of Chicago Booth School of Business | Masters Business Admin |
Statistik
International
| Vereinigte Staaten | 5 |
| Frankreich | 3 |
| Vereinigtes Königreich | 2 |
Operativ
| Corporate Officer/Principal | 3 |
| Director of Finance/CFO | 2 |
| Undergraduate Degree | 1 |
Sektoral
| Health Technology | 4 |
| Finance | 3 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| MERRILL LYNCH PREFERRED CAPITAL TRUST I | Finance |
| PHARNEXT SCA | Health Technology |
| REDX PHARMA PLC | Health Technology |
| Private Unternehmen | 2 |
|---|---|
MTS Health Partners LP
MTS Health Partners LP Investment Banks/BrokersFinance MTS Health Partners LP provides strategic and financial advisory services to healthcare companies from global corporations to venture backed businesses. Its strategic advisory alternatives include mergers, acquisitions, company sales, divestitures, recapitalizations, restructurings, general strategic advisory, financing oversight and oversight opinions. The firms financing solutions include traditional private convertible preferred issuances, cross-over focused convertible transactions, common stock and structured/convertible PIPEs, registered direct and acquisition financings, secondary sales, special situations, structured debt financings and royalty monetization. The company was founded by Curtis Scott Lane in 2000 and is headquartered in New York, NY. | Finance |
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Health Technology |
- Börse
- Insiders
- Peter Collum
- Erfahrung